Biora Therapeutics, Inc. (BIOR)
NASDAQ: BIOR · IEX Real-Time Price · USD
0.730
-0.008 (-1.03%)
At close: May 17, 2024, 4:00 PM
0.749
+0.019 (2.63%)
After-hours: May 17, 2024, 7:53 PM EDT
Company Description
Biora Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing oral biotherapeutics in the United States.
The company offers NaviCap, a targeted oral delivery platform for delivery of therapeutics in the gastrointestinal tract to enhance the treatment of inflammatory bowel diseases; and BioJet, a systemic oral delivery platform designs to replace injection with needle-free, oral delivery of large molecules for management of chronic diseases.
The company was formerly known as Progenity, Inc. and changed its name to Biora Therapeutics, Inc. in April 2022 to reflect its focus on its therapeutics pipeline.
Biora Therapeutics, Inc. was founded in 2010 and is headquartered in San Diego, California.
Biora Therapeutics, Inc.
Country | United States |
Founded | 2010 |
IPO Date | Jun 19, 2020 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 58 |
CEO | Aditya P. Mohanty M.B.A. |
Contact Details
Address: 4330 La Jolla Village Drive, Suite 200 San Diego, California 92122 United States | |
Phone | 855-293-2639 |
Website | bioratherapeutics.com |
Stock Details
Ticker Symbol | BIOR |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
IPO Price | $15.00 |
CIK Code | 0001580063 |
CUSIP Number | 74319F107 |
ISIN Number | US74319F3055 |
Employer ID | 27-3950390 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Aditya P. Mohanty M.B.A. | Chief Executive Officer and Director |
Eric d'Esparbes | Chief Financial Officer |
Clarke Neumann J.D. | Senior Vice President, General Counsel and Secretary |
Eric Fox | Vice President of Finance and Accounting & Treasurer |
Troy Seelye | Chief Information Officer |
George Gianakopoulos | Senior Vice President of Sales |
Robyn Hatton | Head of Human Resources |
Kevin Howe Ph.D. | Senior Vice President of Strategic Operations |
Dr. Sharat Singh Ph.D. | Head of Research |
Dr. Paul Shabram M.B.A. | Head of Technical Operations |
Latest SEC Filings
Date | Type | Title |
---|---|---|
May 15, 2024 | 10-Q | Quarterly Report |
May 15, 2024 | 8-K | Current Report |
Apr 24, 2024 | ARS | Filing |
Apr 24, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
Apr 24, 2024 | DEF 14A | Other definitive proxy statements |
Apr 17, 2024 | EFFECT | Notice of Effectiveness |
Apr 12, 2024 | PRE 14A | Other preliminary proxy statements |
Apr 12, 2024 | UPLOAD | Filing |
Apr 8, 2024 | S-3 | Registration statement under Securities Act of 1933 |
Apr 2, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |